Paris Cedex 12

• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Not authorised
  2024-515603-19-00 4 Localized digestive Neuroendocrine Carcinomas
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Elranatamab Post Trial Access Study for Participants With Multiple Myeloma Pending
  2023-505200-33-00 5 Multiple myeloma
• SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss Pending
  2024-513710-35-00 5 Patients presenting to ENT emergencies with a unilateral sudden sensor
• PRESENT - Prophylaxis of Recurrent Erysipelas in lower limbs: compreSsion thErapy vs aNTibiotics and compression therapy. A non-inferiority, … Pending
  2024-513801-30-00 5 Recurrent Erysipelas in lower limbs
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy … Pending
  2024-514388-24-00 4 Knee osteoarthritis
• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 5 ulcerative colitis
• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Pending
  2024-515603-19-01 4 Localized digestive Neuroendocrine Carcinomas
• Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending
  2024-516052-17-01 10 Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
• A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse Pending
  2024-516257-44-00 4 Multiple myeloma
• A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP … Pending
  2024-516570-30-00 4 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
• Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct … Pending
  2024-518139-12-00 4 locally advanced or metastatic Pancreatic ductal adenocarcinoma
• PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending
  2024-519753-11-00 4 Resectable borderline pancreatic adenocarcinoma
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed mult … Pending
  2025-520976-25-00 4 Relapsed/refractory multiple myeloma
• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Pending
  2025-524056-63-00 1 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Pending
  2025-524573-16-00 6 Crohn's disease
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On-demand Treatment of Angioedema Attacks in Adults with Acq … Recruiting
  2025-522051-26-00 5 2026-04-23 Acquired Angioedema due to C1 Inhibitor Deficiency
• Dose-Selection, Safety and Efficacy Study with Open-Label Extension of Choline Chloride for Injection in Adolescent and Adult Patients with … Recruiting
  2024-519496-26-00 10 2025-09-25 Intestinal Failure
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR … Recruiting
  2024-512119-34-00 4 2022-06-20 MSI-H/dMMR metastatic colorectal cancer
• NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The … Recruiting
  2022-500966-82-00 5 2020-03-11 Resectable locally advanced squamous cell carcinoma (SCC) of the esoph

Showing 1–24 of 153 trials